Neurimmune is a biopharmaceutical firm that translates genetic data from human immune repertoires into antibody therapeutics, including the discovery of aducanumab in collaboration with researchers at the University of Zurich and its licensing to Biogen. Neurimmune partners with Biogen on the development of aducanumab, which is a human monoclonal antibody aimed at removing beta amyloid in the brains of Alzheimer's disease patients, and is co-developed with Eisai. Biogen intends to file for regulatory approval of aducanumab in Alzheimer's disease following positive results from a significant Phase 3 study demonstrating clinical benefit.
Neurimmune
Headquarters
Switzerland